Modified Chemo Drug Kills More Cancer Cells, Activates Immune Cells—and Has Fewer Toxicities

Elisa Becze, BA, ELS, Editor


Once abandoned because of dose-limiting toxicities, a novel chemotherapy drug is showing even more promise as a modified prodrug. In study results published in Science Advances, researchers demonstrated how turning DRP-104 into a prodrug enables it to kill more tumor cells and activate CD8+ T cells with a “markedly improved tolerability profile.”

View Article @

ONS Voice Articles

ONS's member magazine articles.

View All Voice Articles